Kentera

Selected form

Oxybutynin

Method of action: Antispasmodic, Myotropic, Urologicals

Treatment option: Enuresis, Incontinence, Unstable Bladder, Cystitis, Urinary Frequency

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kentera

Property	Description
Active ingredient	Oxybutynin (as the chloride salt)
Form	Transdermal patch (Transdermal system)
Pharmacological class	Anticholinergic agent / Antimuscarinic
Common use	Improving bladder control and reducing urinary urgency
Origin	Synthetic (Tertiary amine derivative)

What Type of Medicine is Kentera? (Identity and Classification)

Kentera is the brand name for a synthetic medicinal product delivered through a transdermal patch that contains the active ingredient oxybutynin chloride. The drug is classified as an anticholinergic agent and functions as a urinary antispasmodic. This classification means the medicine is specifically designed to reduce spasms or sudden, involuntary contractions in the smooth muscles of the urinary tract. Oxybutynin belongs to the antimuscarinic pharmacological subclass, a class recognized for its efficacy in modulating neurological signals that control the bladder.

The unique differentiating factor for the Kentera brand is its delivery as a transdermal system, which contrasts it with other common oxybutynin products that are taken orally. This specific formulation establishes a controlled release profile, which is beneficial for adult patients seeking continuous symptom management.

Understanding the Composition and Form (Active Ingredient and Delivery)

The active ingredient in Kentera is oxybutynin, which is administered as a racemate comprising R- and S-isomers, within a transdermal patch dosage form. This formulation is intended for single component transdermal delivery, meaning the medication is continuously absorbed through the skin. Oxybutynin is categorized as a tertiary amine. This delivery method is specifically intended to bypass the extensive initial metabolism that affects oral medications, helping to ensure a stable therapeutic concentration of the compound over the application period.

The General Purpose of Kentera (High-Level Benefit)

The core purpose of Kentera is to improve overall bladder control by restoring more stable function to the bladder wall. The physiological action of oxybutynin is to diminish the frequency of uninhibited contractions of the detrusor muscle. Its general therapeutic benefit is mitigating patient discomfort and disruption associated with urinary frequency and the compelling sensation of urinary urgency, offering relief in a typical use scenario where patients require continuous, round-the-clock symptom control.

Regulatory References

NIH Drug Information for Oxybutynin

What side effects are possible with Kentera?

Possible Side Effects and Safety Information

The safety profile of the oxybutynin transdermal system is formally characterized by government regulatory authorities based on system-organ classes and frequency of occurrence.

Frequency-Classified Adverse Reactions

The most commonly documented adverse reactions reflect both the application method and the pharmacology of the medicine. Application site pruritus (itching) is listed as very common (ge 1/10). Reactions classified as common (ge 1/100 to < 1/10) include systemic anticholinergic effects such as dry mouth, constipation, headache, dizziness, and somnolence. Other common effects include nausea, blurred vision, and localized skin reactions like application site erythema or rash.

Systemic and Clinically Significant Safety Concerns

Adverse effects are grouped into system-organ classes, primarily affecting the Gastrointestinal (dry mouth, constipation), Nervous (dizziness, somnolence), and Skin systems (application site reactions). Less common effects include palpitations and urinary retention.

Serious adverse reactions documented in regulatory sources include reports of Angioedema (swelling of the face or throat) and severe Hypersensitivity Reactions. The label also notes that potent anticholinergic effects, such as confusion or cognitive impairment, are a potential concern, particularly in susceptible populations.

Population and Use Restrictions

Specific safety considerations exist for certain groups. Older adults may be more susceptible to central nervous system (CNS) effects. The medicine is contraindicated and must not be used in individuals with conditions such as uncontrolled narrow-angle glaucoma, urinary retention, or severe gastric retention. Furthermore, the label notes that application site reactions are frequently reported at the start of treatment.

Overdose and Emergency Response

The official overdose profile for the Kentera transdermal system is defined by the severe manifestation of anticholinergic effects and the risk to multiple physiological systems. Documented overdose presentations may include pronounced signs of CNS excitation, such as agitation, confusion, disorientation, and elevated body temperature presenting as fever and flushing. Severe outcomes are associated with life-threatening events, including profound neurological changes like stupor and cardiovascular effects such as cardiac arrhythmia. Urinary retention is also listed as a potential physiological finding.

Emergency Actions and Monitoring	Official Regulatory Statements
When to Seek Urgent Help	Immediate medical help is required when life-threatening signs occur, including seizure, collapse, or trouble breathing; individuals must immediately call emergency services (911) or call the poison control helpline.
Initial Management	Management requires the removal of the transdermal system(s). The plasma concentration of oxybutynin declines within 1 to 2 hours after the system is removed.
Supportive Care	Treatment is described as symptomatic and supportive treatment, as no specific antidote is named in the regulatory materials. Patients must be monitored until symptoms resolve.

The regulatory guidance centers on prompt intervention and supportive care. The required procedural action is the removal of the transdermal system, followed by continuous monitoring until all documented symptoms abate. No population-specific overdose notes are explicitly documented in the official regulatory sections for the transdermal patch.

Therapeutic Uses of Kentera

What Kentera Treats: Main Uses and Benefits

This medication is used to provide supportive management for symptoms related to Overactive Bladder (OAB). It is indicated for the symptomatic treatment of manifestations related to functional bladder stress. The medication is relevant for easing challenging symptoms, including urinary urgency, increased frequency, and urge incontinence.

It is commonly used in conditions characterized by periods of heightened symptoms and is applied across domains where additional symptomatic support is needed. This treatment may be part of symptomatic management for sustained relief, often used when symptoms intensify and supportive relief is needed to manage the overall symptom burden.

“This approach assists with maintaining functional stability and coping more steadily with symptom fluctuations.”

By addressing symptoms that create noticeable physiological strain, the treatment helps patients maintain a sense of stability when symptoms become more disruptive. It contributes to improved comfort during symptomatic periods and provides supportive relief when symptoms interfere with routine activities.

Quick Fact: Support for Urinary Urgency This medication may assist in managing the sudden, compelling need to pass urine, which is a primary symptom that interferes with daily functioning.

Eligibility and Restrictions for Use

Who Can and Cannot Use Kentera?

The official regulatory profile for Kentera (oxybutynin transdermal system) defines strict population-based eligibility based on age, specific medical conditions, and physiological status.

Contraindicated Populations (Absolute Non-Eligibility)

Use of Kentera is contraindicated and must not be used in patients with:

Hypersensitivity (allergy) to oxybutynin or any patch excipients.
Narrow-angle glaucoma or those at risk for this condition.
Myasthenia gravis.
Urinary retention or clinically significant bladder outflow obstruction.
Severe gastro-intestinal conditions (e.g., intestinal atony, severe ulcerative colitis) or those at risk for them.

Age-Related and Conditional Eligibility Rules

Population Group	Official Eligibility Status
Adults	Approved population for use.
Pediatric Population	Safety and efficacy not established; not recommended for children or adolescents.
Elderly Patients	Requires caution due to potential sensitivity to anticholinergic effects.
Hepatic/Renal Impairment	Requires caution; use in hepatic impairment must be carefully monitored.
Pregnancy	Not to be used unless clearly necessary.
Lactation (Breastfeeding)	Use is not recommended.

Connection to the Overall Eligibility Profile

The eligibility profile is defined by specifying that use is limited to adult patients and is contraindicated for several populations whose conditions, such as narrow-angle glaucoma or urinary retention, could be worsened by anticholinergic action. Furthermore, regulators define populations—such as those with organ impairment or neurological conditions—in which use is restricted and requires caution and monitoring.

What should I know about interactions with other medicines?

The regulatory profile for Kentera (oxybutynin transdermal system) documents specific interaction patterns that must be considered during co-administration with other substances.

Pharmacodynamic Interactions

Co-administration with other medicinal products that possess anticholinergic activity is noted to increase the overall anticholinergic effects of oxybutynin. This category includes agents such as antiparkinsonian medicines, certain antihistamines, and some antipsychotics (like phenothiazines). Due to its effect on gastrointestinal smooth muscle, oxybutynin may also exert a functional antagonism against prokinetic therapies, potentially altering the absorption of these and other concomitantly administered drugs. Furthermore, the official labeling notes that alcohol may enhance the drowsiness associated with anticholinergic agents.

Pharmacokinetic and Exposure Risk

The official labeling identifies a risk for interaction with strong inhibitors of the CYP3A4 enzyme, which is involved in oxybutynin metabolism. Medicinal products such as certain macrolide antibiotics (e.g., erythromycin) and azole antifungals (e.g., ketoconazole) are examples of CYP3A4 inhibitors. Competition for this metabolic pathway may lead to increased systemic exposure of oxybutynin, potentially heightening its effects. Co-administration with CYP3A4 inhibitors cannot be ruled out as a cause of increased effects.

Population Considerations

A specific interaction-related caution is documented for elderly patients. This population may exhibit increased sensitivity to the central nervous system effects of anticholinergics, making the effects of pharmacodynamic interactions potentially more pronounced in this group.

Mechanism of Action

Muscarinic Receptor Blockade

Kentera (oxybutynin) acts as a competitive antagonist primarily targeting the muscarinic acetylcholine receptors (M1, M2, and M3 subtypes) located in the smooth muscle of the detrusor. By binding to these post-ganglionic receptors, the compound inhibits the action of the neurotransmitter acetylcholine. This modulates an overactive signaling frequency within the parasympathetic pathway, modifying early molecular steps that regulate bladder muscle contraction.

Smooth Muscle Relaxation

The mechanism includes an additional, non-receptor-mediated antispasmodic action exerted directly on the smooth muscle cells. This secondary mechanism is linked to the modulation of transmembrane calcium channel activity, which influences intracellular calcium concentrations critical for muscle contraction. This dual activity regulates an overactive contractile process, resulting in decreased muscle tone and an alteration of smooth muscle cell length-tension dynamics.

️ Detrusor Activity Modulation

The cumulative pharmacodynamic influence affects the detrusor muscle, a structure responsible for bladder wall tension. By suppressing the signaling sequences that initiate involuntary detrusor contractions, the mechanism reduces the influence of excessive mediator activity, thereby promoting a lower level of basal muscle activation within targeted pathways.

Dosage and Administration Information

How to Use Kentera (Oxybutynin Transdermal System)

Kentera is an oxybutynin transdermal patch applied to the skin for continuous drug delivery.

Administration and Dosage

Use Entity	Official Instructions
Route	Transdermal (to the skin) only.
Dose	One 3.9 mg/24 hours patch.
Frequency	Twice weekly (changed every 3 to 4 days).

Application Procedures

Schedule: The patch must be changed on the same two days each week (e.g., Sunday and Wednesday) to maintain the prescribed twice-weekly schedule.
Application: Apply one patch immediately after removing it from its protective sachet to a clean, dry, and smooth area of skin on the abdomen, hip, or buttock.
Site Rotation: Crucially, a new application site must be selected with each patch change. The previous site must not be reused for at least 7 days to avoid skin irritation and ensure proper absorption.
Handling: The transdermal system must not be cut or divided and only one patch should be worn at a time. The patch should be worn under clothing to avoid exposure to the sun.

Population-Specific Rules

Pediatrics: The safety and effectiveness of Kentera have not been established in children and adolescents, and its use is not recommended.
Hepatic/Renal Impairment: Use should be undertaken with caution and patients must be carefully monitored.

Recent Clinical Evidence

Research evidence / Overview of Studies for Kentera

This section describes the types of clinical research conducted on the oxybutynin transdermal patch and what the findings generally suggest, based on official and peer-reviewed scientific sources. The overview focuses on how symptoms were tracked in group settings and highlights what is still uncertain in the research landscape.

Evidence for Use in Overactive Bladder (OAB) Symptoms

The primary evidence used in research exploring how symptoms change over time for the transdermal patch comes from randomized, double-blind, placebo-controlled trials (RCTs). These short-term studies were used to examine how patients experienced conditions characterized by fluctuating or episodic manifestations of OAB. Researchers focused on outcomes related to physical discomfort and systemic or functional imbalance.

In these trials, the studies monitored changes in outcomes related to daily urinary incontinence episodes and the number of daily urinations (frequency). Studies reported patterns in measured outcomes and patient experiences that varied between the transdermal patch group and the placebo group over the defined time intervals. These studies contribute to the broader evidence landscape by helping to contextualize how groups of patients reported their experience when symptoms became more noticeable.

It is important to understand that research provides context but not individual predictions. The findings describe group patterns, and research does not determine whether an individual will respond similarly to the trends observed.

Comparison of Delivery Methods in Clinical Trials

Research also explored how the oxybutynin transdermal patch was studied in relation to other treatment formats for OAB. Comparative RCTs were conducted where the transdermal patch was studied for its effect compared to oral formulations of oxybutynin and other medications in the same pharmacological class. These trials were relevant in evidence describing how symptoms are measured when comparing different delivery methods.

The studies explored short-term symptom changes, focusing on episodes where symptoms become more noticeable. Some research reported patterns related to outcomes reflecting daily functioning or activity level across these different medication delivery types. Studies examined and reported outcomes describing episodic or acute changes for the transdermal patch and for other established OAB treatments in the short-term research period. This evidence describes the outcomes observed in the research settings.

Frequently Asked Questions (FAQ)

Common questions about Kentera (FAQ)

Q: What should I do if my patch falls off before the 3-4 days are up?

Regulatory documents indicate that if the patch falls off, the person may reapply the same patch or apply a new one if the original cannot be secured. After this, the original twice-weekly treatment schedule should be continued. Consult the official instructions for complete guidance on missed or detached doses.

Q: Can I shower, swim, or bathe while wearing the patch?

The product information states that the Kentera patch is designed to remain in place when showering, bathing, or swimming. If, however, the patch detaches or falls off prematurely, the official instructions for applying a new patch should be consulted.

Q: How does Kentera work in the body?

Kentera is classified as an anticholinergic agent. Official labeling explains that it works by blocking certain chemical signals, which helps the bladder muscle (the detrusor muscle) relax. This action reduces involuntary contractions of the bladder, which may help ease symptoms like urinary urgency and frequency.

Q: Are there any foods or drinks I should avoid while using this patch?

Official product labeling indicates that consuming alcohol may increase the feeling of drowsiness or sedation associated with anticholinergic medicines like Kentera. No specific restrictions on foods or other non-alcoholic drinks are typically noted in the product information.

Q: Where on my body should I apply the patch?

Official application instructions advise applying the patch to a clean, dry, and smooth area of skin on the abdomen, hip, or buttock. Furthermore, official instructions specify that a new application site must be chosen each time the patch is changed, and the same site should not be reused for at least seven days.

Q: Can I drink alcohol while on the Kentera patch?

Product labeling notes that individuals may experience an increase in the sedative effect (drowsiness) if alcohol is consumed while using the patch. This information is provided to help individuals understand potential interactions.

Q: Does the patch come in different strengths?

The Kentera transdermal patch is available in one strength. Regulatory documents specify that this single patch is designed to deliver 3.9 mg of the active ingredient (oxybutynin) over a 24-hour period.

Q: Is it safe for pregnant or breastfeeding women to use Kentera?

Official product information provides specific cautions for these groups. Use during pregnancy is generally not recommended unless the medicine is clearly necessary. Similarly, use for breastfeeding women is not recommended by the manufacturer.

How should Kentera be stored and disposed of?

How to Store and Dispose of Kentera (Oxybutynin Transdermal Patch)

The storage and disposal of Kentera must adhere strictly to official regulatory guidelines to maintain product integrity and prevent harm.

Storage Condition
Prohibited Temperatures	Must not be refrigerated or frozen [1].
Container Integrity	The patch must be kept sealed in its original sachet until immediate application [2].
Child Safety	Store the product, both unused and used, out of the sight and reach of children [3].

For disposal, patches still contain the active ingredient after use and require careful handling. Used patches must be folded in half with the adhesive sides facing inward, placed back into the original sachet, and discarded safely. It is explicitly forbidden to flush used Kentera patches down the toilet or throw them into household wastewater to protect the environment [4]. Unused or expired patches should be returned to a pharmacy or discarded according to local pharmaceutical waste requirements [5].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.